FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Veness Adam M

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/5/2019 

3. Issuer Name and Ticker or Trading Symbol

ACCELERON PHARMA INC [XLRN]

(Last)        (First)        (Middle)

128 SIDNEY STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
VP, General Counsel and Sec. /

(Street)

CAMBRIDGE, MA 02139       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   19631   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock     (1) 1/25/2029   Common Stock   8500   $41.64   D    
Option to Purchase Common Stock     (2) 3/1/2028   Common Stock   7650   $40.61   D    
Option to Purchase Common Stock     (3) 3/2/2027   Common Stock   5200   $30.17   D    
Option to Purchase Common Stock     (4) 3/3/2026   Common Stock   6000   $27.97   D    
Option to Purchase Common Stock     (5) 1/8/2025   Common Stock   1450   $41.20   D    
Option to Purchase Common Stock     (6) 8/1/2024   Common Stock   4500   $29.37   D    

Explanation of Responses:
(1)  The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019.
(2)  The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.
(3)  The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017.
(4)  The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2016.
(5)  The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2015.
(6)  The shares of common stock underlying this stock option award vested 25% on July 14, 2015 and in equal installments quarterly thereafter.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Veness Adam M
128 SIDNEY STREET
CAMBRIDGE, MA 02139

VP, General Counsel and Sec.

Signatures
/s/ Adam M. Veness 6/7/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Acceleron Pharma.